AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division
News Mar 02, 2006
Albany Molecular Research, Inc. has announced that Michael A. Guaciaro, Ph.D. has assumed leadership responsibility for the Hungarian facilities, and is relocating to Budapest.
ComGenex Chief Executive Officer Laszlo Urge, Ph.D. will remain with AMRI in Budapest and serve as a key member of the leadership team there.
Since joining AMRI in 2001, Dr. Guaciaro has led over 40 drug discovery project teams and has played a key role in the support and coordination of medicinal chemistry projects at the company's R&D centers in Singapore and India.
Prior to joining AMRI, Dr. Guaciaro worked at American Cyanamid Agricultural Research Center, where he was involved in the integration of research programs between sites in the United States and Europe. He obtained a Ph.D. in organic chemistry from the University of Pennsylvania.
"Dr. Guaciaro is a veteran scientist with 25 years of professional industry experience and has created an impressive record of accomplishment during his tenure at AMRI," said D'Ambra.
"His research teams have discovered and developed several pre-clinical and clinical candidates in a number of therapeutic areas on behalf of our customers."
"We are pleased that Dr. Guaciaro has accepted this exciting opportunity to lead our European operations. I look forward to working closely with him as we continue to integrate ComGenex into the AMRI corporate family."
"We are also pleased that Dr. Urge has agreed to remain with AMRI. His experience and leadership will be critical, both during the short-term transition period and in helping us to achieve our long-range goals."
"He will be working closely with Dr. Guaciaro and the scientific team in Budapest to make this a successful effort."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE